Sign up to save your podcasts
Or
Share Ep. 156 - JPM Highlights & Alzheimer's Takeaways
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Ep. 156 - JPM Highlights & Alzheimer's Takeaways
A trio of billion dollar deals for late-stage and commercial assets featuring contingent value rights were among the highlights of the first day of the J.P. Morgan Healthcare Conference in San Francisco on Monday. BioCentury's editors discuss AstraZeneca's takeout of CinCor, Ipsen's buy of Albireo and Chiesi's acquisition of Amryt as well as other takeaways from JPM, the CERSI summit and the Neuroscience Innovation Forum. The team also discusses the latest in Alzheimer's.
Reach us by sending a text
View all episodes
By BioCentury
4.8
3232 ratings
A trio of billion dollar deals for late-stage and commercial assets featuring contingent value rights were among the highlights of the first day of the J.P. Morgan Healthcare Conference in San Francisco on Monday. BioCentury's editors discuss AstraZeneca's takeout of CinCor, Ipsen's buy of Albireo and Chiesi's acquisition of Amryt as well as other takeaways from JPM, the CERSI summit and the Neuroscience Innovation Forum. The team also discusses the latest in Alzheimer's.
Reach us by sending a text
More shows like BioCentury This Week
View all
Freakonomics Radio
32,246 Listeners
Bloomberg Intelligence
406 Listeners
Odd Lots
1,993 Listeners
Nature Podcast
756 Listeners
The Long Run with Luke Timmerman
125 Listeners
The Readout Loud
337 Listeners
Making Sense
71 Listeners
Thoughts on the Market
1,320 Listeners
Biotech 2050 Podcast
61 Listeners
Business Of Biotech
85 Listeners
MIT Technology Review Narrated
263 Listeners
Biotech Hangout
21 Listeners
WSJ's Take On the Week
150 Listeners
The Top Line
17 Listeners
The BioCentury Show
11 Listeners